文献速递临床试验与 GCP

免疫球蛋白联合泼尼松龙减少川崎病患者冠状动脉病变的效果:一项III期多中心、开放标签、终点盲法随机对照试验的研究方案

Effects of immunoglobulin plus prednisolone in reducing coronary artery lesions in patients with Kawasaki disease: study protocol for a phase III multicenter, open-label, blinded-endpoints randomized controlled trial.
PubMed 文献 · Trials · 2021-12-11

本研究为多中心、前瞻性、开放标签、终点盲法随机对照试验,计划在中国20余家医院开展,评估静脉注射免疫球蛋白(IVIG)联合泼尼松龙对比标准治疗(IVIG联合阿司匹林)在川崎病患者中减少冠状动脉病变(CAL)的疗效与安全性。主要结局为发病1个月时CAL的发生情况,随访1年。

要点

  • 纳入符合标准的川崎病患者,按1:1随机分为IVIG+阿司匹林组与IVIG+阿司匹林+泼尼松龙组。
  • 主要结局为发病1个月时冠状动脉病变的发生情况,随访期1年。
  • 该试验旨在为中国川崎病患儿初始治疗提供高级别证据。

核心结论

  • 本试验将评估在标准IVIG联合阿司匹林治疗基础上加用泼尼松龙能否减少中国川崎病患者冠状动脉病变的发生。

研究设计与样本

  • 多中心、前瞻性、开放标签、随机对照试验,计划在中国20余家医院开展。
  • 纳入符合 inclusion 和 exclusion 标准的川崎病患者,按1:1随机分组。

主要发现

  • 主要结局为发病1个月时CAL的发生情况,随访期1年。
  • 试验组方案为IVIG(2 g/kg,12-24小时输注,最大剂量60 g)+阿司匹林30 mg/kg/d+泼尼松龙(2 mg/kg/d,最大剂量60 mg,C反应蛋白浓度正常后15天内逐渐减量)。
  • 对照组方案为IVIG(2 g/kg,12-24小时输注,最大剂量60 g)+阿司匹林30 mg/kg/d。

关键数值与推荐

  • 主要结局指标为发病1个月时CAL的发生情况。
  • 泼尼松龙用法:2 mg/kg/d,最大剂量60 mg,C反应蛋白正常后15天内逐渐减量。
  • IVIG用法:2 g/kg,12-24小时输注,最大剂量60 g。
  • 阿司匹林用法:30 mg/kg/d。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Kawasaki disease (KD) is an acute systemic vasculitis of unclear etiology that mainly affects infants and young children. Strategies to reduce the incidence and severity of coronary artery lesions (CALs), the determinant factor in the long-term prognosis of KD, are currently a focus of studies on KD. Corticosteroids, preferred in the treatment of the majority of vasculitides, are controversial in the treatment of acute KD. In this trial, we will evaluate whether the addition of prednisolone to standard intravenous immunoglobulin (IVIG) plus aspirin therapy can reduce the occurrence of CAL in Chinese patients with KD. METHODS: This is a multicenter, prospective, open-label, randomized controlled trial, which is expected to be conducted in more than 20 hospitals in China and aims to assess the efficacy and safety of IVIG + prednisolone treatment versus standard treatment. Patients with KD who fulfill the inclusion and exclusion criteria will be recruited and randomized (1:1) to receive either a large dose of IVIG (2 g/kg over 12-24 h with a maximum dose of 60 g) + aspirin 30 mg/kg/d or IVIG (2 g/kg over 12-24 h) + aspirin 30 mg/kg/d + prednisolone (2 mg/kg/d with a maximum dose of 60 mg tapered over 15 days after normalization of C-reactive protein concentration). The primary outcome will be the occurrence of CAL at 1 month of illness. The follow-up duration for each participant will be set as 1 year. Patients and treating physicians will be unmasked to group allocation. DISCUSSION: This will be the first multicenter randomized controlled trial to evaluate the efficacy of IVIG + aspirin + prednisolone in Chinese pediatric patients with KD, which may provide high-level evidence for improving the initial treatment for acute KD. TRIAL REGISTRATION: ClinicalTrials.gov NCT04078568 . Registered on 16 August 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Lin SY, He L, Xie LP, et al. Effects of immunoglobulin plus prednisolone in reducing coronary artery lesions in patients with Kawasaki disease: study protocol for a phase III multicenter, open-label, blinded-endpoints randomized controlled trial. Trials. 2021. PMID: 34895290. doi:10.1186/s13063-021-05807-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。